Literature DB >> 34012665

A systematic review and meta-analysis of radio frequency ablation and routine resection in the treatment of small hepatocellular carcinoma.

Yu Li1, Weike Xiao1, Zhenrong Gao1.   

Abstract

BACKGROUND: This study sought to conduct a meta-analysis of the relevant literature on radiofrequency ablation (RFA) and routine resection in the treatment of small hepatocellular carcinoma (SHCC) in recent years, and to examine the clinical efficacy and safety of different schemes.
METHODS: PubMed, The Cochrane Library, Embase, CNKI, Chinese biomedical literature, VIP Chinese journal and the Wanfang Database were used to comprehensively search for relevant papers on clinical control studies of RFA and the routine resection SHCC published between January 2008 and December 2019. The clinical efficacy and safety of different schemes in the treatment of SHCC were compared, including the overall survival rate within 1, 3, and 5 years, and the incidence of complications during treatment. A meta-analysis was undertaken using methods provided by the Cochrane Collaboration and RevMan 5.3 software.
RESULTS: A total of 13 publications of studies were retrieved in which 2,384 patients participated. Of these patients, 1,256 (52.68%) were allocated to the RFA group and 1,128 patients (47.32%) to the conventional resection group. The effect size of the 1-year overall survival rate for the two groups was odds ratio (OR): 0.78 [95% confidence interval (CI), 0.43-1.38]; Z test: P=0.32. The effect size of the overall survival rate within 3 years was OR: 0.71 (95% CI, 0.48-1.05); Z test: P=0.07. The difference was not statistically significant. The 5-year overall survival rate of the RFA group and conventional resection group was OR: 0.55 (95% CI, 0.40-0.72). The OR value fell within the CI, excluding 1; Z test: P<0.0001. The difference was statistically significant. The incidence of complications in the RFA group during treatment was lower than that in the conventional resection group (OR: 0.45; 95% CI, 0.32-0.69). The OR value was within the CI, excluding 1; Z test: P=0.0002. The difference was statistically significant.
CONCLUSIONS: The short-term effect of RFA in the treatment of SHCC is basically the same as that of routine resection; however, the long-term effect is significantly lower than that of routine resection. RFA has a lower incidence of complications during treatment, and thus better clinical safety. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Radiofrequency ablation (RFA); efficacy; meta-analysis; routine resection; safety; small hepatocellular carcinoma (SHCC)

Year:  2021        PMID: 34012665      PMCID: PMC8107575          DOI: 10.21037/jgo-21-52

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  25 in total

1.  [Colorectal resection combined with simultaneous radiofrequency ablation in the treatment of synchronous colorectal liver metastases: a retrospective analysis].

Authors:  Y L Guo; Z H Tong; X Xu; Y Zhao; J W Liu; H G Wang; G L Dong
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2017-03-28

Review 2.  Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis.

Authors:  Madhav Desai; Shreyas Saligram; Neil Gupta; Prashanth Vennalaganti; Ajay Bansal; Abhishek Choudhary; Sreekar Vennelaganti; Jianghua He; Mohammad Titi; Roberta Maselli; Bashar Qumseya; Mojtaba Olyaee; Irwing Waxman; Alessandro Repici; Cesare Hassan; Prateek Sharma
Journal:  Gastrointest Endosc       Date:  2016-09-23       Impact factor: 9.427

3.  [Combined liver resection and radiofrequency ablation for colorectal liver metastases].

Authors:  Anne-Sofie Kannerup; Dennis Tømrer Nielsen; Steen Mellerup Sørensen; Frank Viborg Mortensen
Journal:  Ugeskr Laeger       Date:  2008-04-14

4.  Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.

Authors:  Gisèle N'Kontchou; Amel Mahamoudi; Mounir Aout; Nathalie Ganne-Carrié; Véronique Grando; Emmanuelle Coderc; Eric Vicaut; Jean Claude Trinchet; Nicolas Sellier; Michel Beaugrand; Olivier Seror
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

5.  Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.

Authors:  Masashi Hirooka; Atsushi Hiraoka; Hironori Ochi; Yoshiyasu Kisaka; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa
Journal:  AJR Am J Roentgenol       Date:  2018-02-07       Impact factor: 3.959

Review 6.  Radiofrequency Ablation versus Liver Resection for Colorectal Cancer Liver Metastasis: An Updated Systematic Review and Meta-analysis.

Authors:  Yue Han; Dong Yan; Fei Xu; Xiao Li; Jian-Qiang Cai
Journal:  Chin Med J (Engl)       Date:  2016-12-20       Impact factor: 2.628

7.  Surgically treated diaphragmatic perforation after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Sachiko Nagasu; Koji Okuda; Ryoko Kuromatsu; Yoriko Nomura; Takuji Torimura; Yoshito Akagi
Journal:  World J Gastrointest Surg       Date:  2017-12-27

8.  Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study.

Authors:  Wenwu Liu; Zhiwen Yang; Ruhai Zou; Jiliang Qiu; Jingxian Shen; Yadi Liao; Chenwei Wang; Yuanping Zhang; Yongjin Wang; Yichuan Yuan; Kai Li; Dinglan Zuo; Wei He; Yun Zheng; Binkui Li; Yunfei Yuan
Journal:  J Cancer       Date:  2019-06-02       Impact factor: 4.207

9.  Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis.

Authors:  Yi-Bin Xiao; Bo Zhang; Yu-Lian Wu
Journal:  J Zhejiang Univ Sci B       Date:  2018-11       Impact factor: 3.066

10.  Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.

Authors:  Y-M Li; S-C Xu; J Li; K-Q Han; H-F Pi; L Zheng; G-H Zuo; X-B Huang; H-Y Li; H-Z Zhao; Z-P Yu; Z Zhou; P Liang
Journal:  Cell Death Dis       Date:  2013-10-03       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.